The Evidence for Collaborative Care

The primary care course introduced the Collaborative Care Model and its three roles. This lesson covers why it is the model everything else is compared against, which comes down to an unusually strong evidence base.

The IMPACT trial

The landmark randomized controlled trial studied collaborative care for late-life depression across a wide range of primary care practices.

The result: “At 12 months, 45% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline compared with 19% of usual care participants (odds ratio [OR], 3.45; 95% confidence interval [CI], 2.71-4.38; P<.001).”

The authors concluded that “the IMPACT collaborative care model appears to be feasible and significantly more effective than usual care for depression in a wide range of primary care practices.”

An odds ratio of 3.45 with that confidence interval is a large, precisely estimated effect. The evaluation course spent a module on reading magnitude alongside significance; this is what a result looks like when both are strong.

The systematic review

A single trial, however good, is a single trial. A Cochrane systematic review of collaborative care for depression and anxiety found “significantly greater improvement in depression outcomes for adults treated with collaborative care in short-term, medium-term, and long-term periods,” with anxiety outcomes showing “significant improvements across these timeframes” and “evidence of benefit in secondary outcomes including medication use, mental health quality of life, and patient satisfaction.”

The review concluded that “collaborative care is associated with significant improvement in depression and anxiety outcomes compared with usual care, and represents a useful addition to clinical pathways for adult patients with depression and anxiety.”

Randomized evidence, replicated, sustained across time horizons, covering two conditions. This is a stronger foundation than most interventions in this curriculum can claim.

Why it works

Three components carry the effect, and none is exotic:

• Systematic follow-up. Someone is responsible for contacting the patient at intervals rather than waiting for them to return.
• Measurement-based treat-to-target care. Symptoms are measured with a validated instrument, and treatment intensifies when the target is not met.
• Caseload psychiatric consultation. A psychiatrist reviews the care manager’s whole caseload, so scarce expertise reaches many patients.

The first two are what most usual care lacks. A patient started on an antidepressant and told to come back in three months, who does not come back, has received a prescription rather than treatment.

Worth remembering: the evidence here is strong enough that the interesting question is not whether collaborative care works but why it is still not standard. The answer is mostly the operational and financial requirements covered in the next two lessons, and it is worth naming the asymmetry plainly. A drug with this evidence base would be in every guideline and every formulary. A care process with this evidence base has to be separately financed, separately staffed, and separately justified at every organization that adopts it. That difference is about how the payment system treats processes versus products, not about the strength of the science.

Key takeaways

• IMPACT found 45 percent of intervention patients achieved a 50 percent symptom reduction at 12 months against 19 percent in usual care.
• A Cochrane review confirmed benefit for depression and anxiety across short, medium, and long-term horizons.
• The active ingredients are systematic follow-up, measurement-based treat-to-target care, and caseload consultation.
• The evidence is strong; the barriers to adoption are operational and financial rather than scientific.

Sources

• Unützer et al., Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial, JAMA 2002 (opens in a new tab)
• Archer et al., Collaborative care for depression and anxiety problems, Cochrane Database of Systematic Reviews 2012 (opens in a new tab)